Biodesix 3Q 2026: Revenue $24.04M, EPS ($0.75) — 10-Q Summary

Biodesix's third-quarter revenue rose 10% year over year, while its net loss narrowed 8%. Diagnostic testing growth, driven by a 24% increase in test volume, was partly offset by lower average revenue per test; Development Services revenue fell on project timing and prior-year contract recognition…